BMEA vs. ANNX, PEPG, TBPH, FULC, CRBP, HRTX, SLRN, MREO, LXRX, and ESPR
Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Annexon (ANNX), PepGen (PEPG), Theravance Biopharma (TBPH), Fulcrum Therapeutics (FULC), Corbus Pharmaceuticals (CRBP), Heron Therapeutics (HRTX), Acelyrin (SLRN), Mereo BioPharma Group (MREO), Lexicon Pharmaceuticals (LXRX), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical preparations" industry.
Biomea Fusion (NASDAQ:BMEA) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.
Biomea Fusion currently has a consensus target price of $53.25, suggesting a potential upside of 335.05%. Annexon has a consensus target price of $14.14, suggesting a potential upside of 226.62%. Given Biomea Fusion's higher probable upside, equities research analysts clearly believe Biomea Fusion is more favorable than Annexon.
Annexon received 12 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 73.33% of users gave Annexon an outperform vote while only 59.26% of users gave Biomea Fusion an outperform vote.
Annexon's return on equity of -56.52% beat Biomea Fusion's return on equity.
Biomea Fusion is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
96.7% of Biomea Fusion shares are owned by institutional investors. 26.3% of Biomea Fusion shares are owned by company insiders. Comparatively, 19.1% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Annexon had 29 more articles in the media than Biomea Fusion. MarketBeat recorded 29 mentions for Annexon and 0 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 1.00 beat Annexon's score of 0.39 indicating that Biomea Fusion is being referred to more favorably in the media.
Biomea Fusion has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.
Summary
Annexon beats Biomea Fusion on 10 of the 15 factors compared between the two stocks.
Get Biomea Fusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomea Fusion Competitors List
Related Companies and Tools
